Author

J. Kluza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1

Frequent Co-Authors

W. Laine· 3 shared A. Machelart· 1 shared A. Poncet· 1 shared A. Trinh· 1 shared A.-M. Pauwels· 1 shared B. Ghesquiere· 1 shared B. Quesnel· 1 shared B. Turcq· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

W. Laine

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Monocyte intrinsic NOD2 signalling inhibits pathogenic macrophage differentiation and its loss in inflammatory macrophages improves intestinal inflammation.

C. Chauvin, D. Alvarez, K. Radulovic, O. Boulard, W. Laine, M. Delacre, N. Waldschmitt, E. Segura, J. Kluza, M. Chamaillard, L. F. Poulin

This study shows that NOD2 signaling in monocytes inhibits their conversion to pathogenic macrophages and its loss worsens intestinal inflammation.

bioRxiv · Oct 6, 2022 · PreprintImmunology

IRG1 controls host responses to restrict Mycobacterium tuberculosis infection

A. Machelart, I. Belhaouane, N. Deboosere, I. Poncin, J.-P. Saint-Andre, A.-M. Pauwels, O.-R. Song, S. Jouny, C. Rouanet, A. Poncet, S. Marion, W. Laine, J. Kluza, E. Muraille, R. Beyaert, , E. Hoffmann

This study shows that IRG1 controls host responses to restrict Mycobacterium tuberculosis infection by modulating immune cell function and limiting bacterial replication.

bioRxiv · May 4, 2022 · PreprintImmunology

ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY APPROVED KIDROLASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS

A. Trinh, R. Khamari, Q. Fovez, F.-X. Mahon, B. Turcq, D. Bouscary, P. Maboudou, M. Joncquel, V. Coiteux, N. Germain, W. Laine, S. Dekiouk, B. Ghesquiere, T. Idziorek, B. Quesnel, , P. Marchetti

This study shows that combining tyrosine kinase inhibitors with Kidrolase targets glutamine metabolism and enhances CML stem cell eradication.

bioRxiv · Sep 21, 2020 · PreprintCancer Biology